Retham Technologies, Inc. — SEC Form D Filing
Retham Technologies, Inc. filed an SEC Form D on September 11, 2026, reporting $1.06M raised in Biotechnology.
Form D filing details
- Filing
- SEC Form D
- Filing date
- September 11, 2026
- Amount reported
- $1.06M
- Industry
- Biotechnology
- Website
- https://www.rethamtechnologies.com/
What the company does
Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE
Problem
Heparin-induced thrombocytopenia (HIT) is a serious adverse reaction to heparin, causing a drop in platelet count and potentially leading to life-threatening blood clots, amputation, stroke, or death. Current diagnostic methods are problematic: widely used PF4 ELISAs have high false positive rates, leading to unnecessary and risky anticoagulant therapy, while the gold-standard Serotonin release assay (SRA) is complex, costly, and has slow turnaround times, making it inaccessible for most patients.
Solution
Retham Technologies is developing HITDx™, an in vitro diagnostic (IVD) assay designed for early, accurate, and technically simple diagnosis of Heparin-induced Thrombocytopenia (HIT). This test aims to be performed near-patient, providing timely results to facilitate appropriate therapy and improve patient outcomes.
Verdict
Investors backed Retham Technologies for its promise of a more efficient diagnostic pathway in a critical, high-stakes medical context. This cleared because the solution directly addressed known diagnostic inefficiencies with a clear "better, faster, cheaper" value proposition for a specific, severe condition, not because the underlying technology demonstrated novel scientific breakthroughs or a broad platform opportunity. The implicit bet was on market adoption driven by superior performance over existing problematic methods. Upside was limited by the narrow scope of the initial application and the inherent market challenges of medical device adoption and regulatory hurdles.
Source: SEC EDGAR Form D filing